AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 103 filers reported holding AKERO THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 4.79 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,075,332 | +433.9% | 21,260 | +392.8% | 0.02% | +475.0% |
| Q2 2023 | $201,421 | +38.9% | 4,314 | -71.8% | 0.00% | +33.3% |
| Q2 2022 | $145,000 | -61.1% | 15,316 | -41.6% | 0.00% | -50.0% |
| Q1 2022 | $373,000 | -27.0% | 26,211 | +8.7% | 0.01% | -14.3% |
| Q4 2021 | $511,000 | -0.4% | 24,111 | +5.2% | 0.01% | 0.0% |
| Q3 2021 | $513,000 | +147.8% | 22,911 | +222.4% | 0.01% | +250.0% |
| Q1 2021 | $207,000 | -74.3% | 7,106 | -72.8% | 0.00% | -80.0% |
| Q3 2020 | $804,000 | – | 26,105 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $179,512,000 | 24.20% |
| venBio Partners LLC | 2,444,311 | $75,260,000 | 11.44% |
| Versant Venture Management, LLC | 777,727 | $23,946,000 | 4.38% |
| Redmile Group, LLC | 2,336,357 | $71,936,000 | 1.32% |
| Vivo Capital, LLC | 571,833 | $17,607,000 | 1.02% |
| Cormorant Asset Management, LP | 859,550 | $26,466,000 | 1.02% |
| Boxer Capital, LLC | 831,495 | $25,602,000 | 0.88% |
| Integral Health Asset Management, LLC | 85,000 | $2,617,000 | 0.80% |
| EAM Global Investors LLC | 49,718 | $1,531,000 | 0.56% |
| Crawford Lake Capital Management, LLC | 43,826 | $1,349,000 | 0.56% |